Komsan Loonprom / Shutterstock.com
24 October 2024NewsAmericasLiz Hockley

Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar

Regeneron loses bid to block Eylea copy at US appeals court | Biotech says decision ‘not the final word’ in litigation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
24 September 2024   Biotech’s motion for preliminary injunction to prevent Eylea biosimilar rejected I Regeneron has filed multiple suits over rivals’ copies of aflibercept.

More on this story

Americas
24 September 2024   Biotech’s motion for preliminary injunction to prevent Eylea biosimilar rejected I Regeneron has filed multiple suits over rivals’ copies of aflibercept.

More on this story

Americas
24 September 2024   Biotech’s motion for preliminary injunction to prevent Eylea biosimilar rejected I Regeneron has filed multiple suits over rivals’ copies of aflibercept.